NovoCure (BSP:N2VC34) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


BSP:N2VC34 NovoCure Ltd BSP:N2VC34
46 GF Score
Price R$7.08
GF Value R$8.98
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is NovoCure Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

NovoCure's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BSP:N2VC34 vs NEOG, ESTA, AXGN: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, NovoCure's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NovoCure Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where NovoCure's Margin of Safety % (DCF Earnings Based) falls into.


BSP:N2VC34
46GF Score
NovoCure Ltd BSP:N2VC34
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NovoCure (BSP:N2VC34) Overvalued in 2026?

Based on GuruFocus' analysis, NovoCure stock appears to be undervalued. The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98. GuruFocus considers NovoCure to be Modestly Undervalued.

Key valuation signals for BSP:N2VC34:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
  • GF Score™: 46/100 with 5 warning signs

No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NovoCure Business Description

Address Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
46GF Score

Get the complete analysis for BSP:N2VC34

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$7.08
Price
R$8.98
GF Value